Eli Lilly and Company (LLY) Trend of Beating EPS and Revenue Estimates

Eli Lilly and Company(LLY) shares saw a recent bid of $78.05 and 2.24M shares have exchanged hands in the recent trading session, yielding a 0.32% gain over the past week. The stock price decreased -0.37% or $0.29 versus $78.34 at the end of the prior session. This change led market cap to move at $86.44B, putting the price -10.00% below the 52-week high and 21.61% above the 52-week low. The company’s stock has a normal trading capacity of 3.93M shares while the relative volume is 0.57.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $89.09 while $102.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $12.91 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $69.00, which would be decrease of about -12% of its current value. The mean target of $90.00 should be compared with the price when the stock was languishing around $64.18 a share. And it remains to be seen which target price LLY can achieve without sacrificing much as the company is holding a 3.35% gain for the past twelve months.

By historical standards, Eli Lilly and Company remains a cheap stock. The company’s current price-earnings ratio amounts to 37.90 times earnings, above the average P/E ratio of 14.27 times earnings. For now, Eli Lilly and Company is the toast of Wall Street as its ABR stands at 2.10 with 7 out of 22 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Eli Lilly and Company has a 0.91% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Eli Lilly and Company has far performed well this year, with the share price up 6.12% since January. Over the past 2 quarters, the stock is up 14.78%, compared with a fall of nearly -6.03% for 3 months and about -4.03% for the past 30 days.

Last time, the company shocked Wall Street by reporting EPS of $0.98, smashing the consensus of $0.96 per share. Revenue for the quarter also killed consensus, coming in at $5.23B, compared to the consensus of 5.22B. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $1.05. The company is expected to report EPS as high as $1.15 and as low as $0.98 per share. Similarly, full-year EPS forecasts have ranged between $4.07 and $4.19. The mean EPS estimate is $4.12. On the other side, sales forecasts for the current quarter are $5.61B. The stock is expected to report revenue as high as $5.7B and as low as $5.5B per share. Similarly, full-year sales forecasts have ranged between $21.89B and $22.33B. The mean revenue estimate is $22.08B.

Over the last 5 years, Eli Lilly and Company has averaged a -8.00% YoY EPS growth rate and a -2.70% revenue growth rate. Analysts are expecting EPS growth rates to be at 14.10% this quarter and EPS estimate for next year reflect a 5.87% growth rate.




Sell-side analysts also have something to say about this company. Argus had a markedly different take on 27/04/2017, proposing that Eli Lilly and Company is now considered Hold versus prior Buy rating. Morgan Stanley had a markedly different take on 17/04/2017, proposing that Eli Lilly and Company is now considered Equal-Weight versus prior Overweight rating. Barclays analysts stated on 07/04/2017 that they maintained their Overweight rating. UBS analysts stated on 20/03/2017 that they maintained their Neutral rating.

Leave a Reply

Your email address will not be published. Required fields are marked *